MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada

BACKGROUND: Evidence supports magnesium sulphate (MgSO4) for women at risk of imminent birth at < 32–34 weeks to reduce the likelihood of cerebral palsy in the child. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP) was a multifaceted knowledge translation (KT) stra...

Descripción completa

Detalles Bibliográficos
Autores principales: De Silva, Dane A., Synnes, Anne R., von Dadelszen, Peter, Lee, Tang, Bone, Jeffrey N., Magee, Laura A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765609/
https://www.ncbi.nlm.nih.gov/pubmed/29325592
http://dx.doi.org/10.1186/s13012-017-0702-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765609/
https://www.ncbi.nlm.nih.gov/pubmed/29325592
http://dx.doi.org/10.1186/s13012-017-0702-9

Ejemplares similares